Issue link: https://www.e-digitaleditions.com/i/1509606
This section provides information that may be useful in research and development or manufacturing. Content is provided by the organizations listed. No endorsement or preference is intended. 34 OctOber 2023 Inhalation SPECIAL SECTION Outsourcing Services This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. Formulation, device and development services Vectura is a specialist inhalation CDMO with 25 years of experience helping customers bring complex inhaled medicines to market by integrating expert formulation and device development services to accel- erate inhaled products through the phases of drug development. With a range of technology platforms, including dry powder inhalers and smart nebulizers, Vectura offers flexibility and expertise to support pro- grams including preclinical safety studies, formula- tion development and device selection, scale-up and GMP product and device manufacturing. Vectura UK: +44 1249 667700 info@vectura.com www.vectura.com OINDP expertise including contract services Proveris® Laboratories offers orally inhaled and nasal drug product development (OINDP) expertise to pharmaceutical developers, including contract services employing new, innovative, in vitro techniques. ese include measuring plume front velocity and evapora- tion rate and quantifying deposition of inhaled drug products using human-realistic models. Employing in vitro approaches that are human-realistic can enable companies to make data-driven decisions and expe- dite product development and approval while saving time and resources. Learn more about these tech- niques and see data we have already published, avail- able on the Proveris website at www.proveris.com/ scientific-posters. Proveris Scientific Corporation US: +1 505 460-8822 contactus@proveris.com www.proveris.com Extractable and leachable studies Extractable and leachable studies are integral to the development process for drug/device combination products. Designing and executing the right study, at the right time, can not only provide necessary safety data, but can also de-risk the overall program. Intertek's world-class E&L group works closely with its Inhaled and Nasal Centre of Excellence in Cam- bridge, UK, supporting all types of respiratory prod- ucts, including pressurized metered dose inhalers (pMDIs), soft mist inhalers (SMIs), nasal sprays, neb- ulizers and dry powder inhalers (DPIs). Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com